Biocytogen’s Post

I am excited to share our 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 has been published in 𝗣𝗵𝘆𝘁𝗼𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗣𝗹𝘂𝘀 (𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗗𝗶𝗿𝗲𝗰𝘁)! Alhamdulillah 🎉 Our study investigates the anti-leukemic potential of 𝗞𝗮𝗲𝗺𝗽𝗳𝗲𝗿𝗼𝗹, a natural compound from fermented horse gram seeds, which demonstrated greater efficacy in HL-60 cells compared to vinblastine. 🔬🧬 DOI: https://lnkd.in/gEgbQKAY 𝗙𝗲𝗿𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 not only boosted the yield of kaempferol but also enhanced its stability and binding affinity to tumor suppressor genes like p53, BAK, and BAX. 𝗧𝗵𝗶𝘀 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗼𝗳𝗳𝗲𝗿𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗻𝗮𝘁𝘂𝗿𝗮𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗹𝗲𝘂𝗸𝗲𝗺𝗶𝗮. 🌿💊 #DrugDiscovery #CancerResearch #Phytomedicine #Leukemia #Kaempferol #Precision #Fermentation #Oncology #Bioactive #p53 #Targeting #HL60 #Innovation #Therapeutics #Anticancer #JamiaHamdard #Biotechnology #Cancer #BloodCancer #Phytocompounds #Moleculardocking #MolecularDynamics #Cytotoxicityassays Dr. Waseem Ali

Cold tumours—such as hepatocellular carcinoma (HCC)—are experts at evading the human immune system, making it difficult to effectively administer treatment. 🤝 Combining immunotherapy (nivolumab) and Y90 radioembolisation treatment could be the key to getting the job done, as seen in a collaborative study by researchers from Singapore, China and Germany. They conducted an in-depth analysis of data from a Phase II trial of the combination therapy, which revealed that patients with a higher tumour mutation burden and 𝙉𝘾𝙊𝙍1 gene mutations were more responsive to the treatment. “The next step is to add in longitudinal immune profiles or other biomarkers as we head towards a multi-omics era for personalised treatments against cancer,” shared Joe YEONG 杨宝诚, a Group Leader at A*STAR’s Institute of Molecular and Cell Biology (IMCB). Head to the comments section for the link to the complete article ⬇️ --- #scicomm #science #technology #STEM #research #innovation #ASTAR #GIS #BII #SIgN #IMCB #HHP #cancer #immunotherapy #livercancer #oncology #collaboration #WorldHealthDay

Congratulations to the research team from Khon Kaen University, Thailand, for their study recently published in the Journal of Traditional and Complementary Medicine. For the first time, the authors provide profound insights into the anti-cancer mechanisms of cannabidiol (CBD) on cholangiocarcinoma (bile-duct cancer) cells. The study reveals that CBD effectively inhibits cell proliferation and colony formation, induces significant structural alterations, disrupts mitochondrial membrane potential, increases mitochondrial ROS generation and overall ROS production, and triggers autophagy. Employing advanced techniques such as Holotomography, the researchers demonstrate that CBD induces lipid droplet accumulation and vesicle accumulation, thereby reshaping cell characteristics in a significant manner. https://lnkd.in/gjCAJZ4K #tomocube #labelfree #livecell #cellimaging #cancer #cancertreatment

A treatment that works well for one patient may not be the best course of action for another, especially when dealing with cold tumours such as in hepatocellular carcinoma (HCC). 🔍 A collaborative study by researchers from Singapore, Germany and China identified predictive biomarkers in patients with HCC which influenced their response to a combined immunotherapy (nivolumab) and Y90 radioembolisation treatment. Data from the Phase II trial of the combination therapy revealed that patients with a higher tumour mutation burden and 𝑵𝑪𝑶𝑹1 gene mutations were more likely to be responsive to the treatment. On the other hand, many patients who responded poorly to the treatment were found to exhibit Kaya_P2, a molecular signature specific to Asian genomes—prompting further research into the treatment’s efficacy among ethnicities. This #ThrowbackThursday, revisit their work in the article linked below ⬇️ --- #scicomm #science #technology #STEM #research #innovation #ASTAR #GIS #BII #SIgN #IMCB #HHP #cancer #immunotherapy #livercancer #oncology #collaboration

#PaperoftheDay: "Notch1 signaling pathway promotes growth and metastasis of gastric cancer via modulating CDH5" DOI ⬇️ https://lnkd.in/egP4ai8M #aging #gastriccancer #research #openaccess #peerreview #publishing

Chimeric antigen receptor T-cell (CAR-T) therapy targeting the B-cell maturation antigen (BCMA) has been shown to drastically improve the patient survival of relapsed/refractory multiple myeloma (R/R-MM), a cancer of the bone marrow (BM). However, significantly high rates of relapse as well as short remission times post-treatment warrant a better understanding of the potential resistance and relapse mechanisms. Single-cell RNA sequencing (scRNA-seq) analysis can shed light on such mechanisms. By employing 10x Genomics scRNA-seq technologies, a recent study [1] demonstrated changes in the cellular composition of immune cells in the BM microenvironment before BCMA CAR-T treatment and after relapse. Among the key findings is that the percentage of BCMA-positive cells increased in relapsed patients after treatment and, furthermore, cell-cell communication analyses revealed that MIF and APRIL signaling pathways are key contributors in R/R-MM patient relapse after treatment. [1] https://hubs.ly/Q02hk2yC0 #Solvuu #CART #CellularTherapy #DrugDiscovery #SingleCell #scRNAseq #RNAseq #TargetIdentification #Oncology #BcellMalignancies

A fundamental application of molecular testing lies in risk stratification (cant say risk stratification without sounding like you work in insurance or WallStreet). By identifying specific genetic oddities, we can categorize patients into prognostic groups. This stratification is pivotal for treatment planning, as it allows clinicians to tailor therapeutic regimens based on a patient's likelihood of relapse and overall survival. For instance, patients with favorable genetic profiles may require fewer intensive therapies, while those with adverse risk factors might benefit from more aggressive treatment strategies, including hematopoietic stem cell transplantation (gone are the days of 'everyone gets chemo'). In essence, risk stratification provides a roadmap for navigating the complexities of cancer treatment (oh it sure is complex). This approach ensures that each patient receives the most appropriate and effective care. The result is improved patient outcomes and a higher quality of life for those battling cancer. Molecular testing and risk stratification together form the backbone of modern oncology, highlighting their indispensable role in the fight against cancer. #molecularoncology #moleculartesting #writingtolearn

⚜Single Cell Analysis: Transforming Disease Research and Treatment⚜ 🔯Single cell analysis is a revolutionary tool in biological research and medicine, allowing scientists to examine individual cells for a precise understanding of cellular heterogeneity. 🔯 It dissects tissues down to their basic units, identifying unique cellular behaviors and variations. 🔯It plays a pivotal role in uncovering tumor heterogeneity, aiding in the development of more effective therapeutic strategies. 🔯Single cell technologies are enhancing the drug discovery process, enabling the design of more targeted and efficient treatments. 🔯 It allows tracking genetic variability and disease progression at an unprecedented resolution, opening doors for early diagnosis and tailored treatment plans. 🔯 As single cell technologies advance, they will revolutionize the way we diagnose diseases and develop therapies, leading to more effective treatments for a wide range of conditions. #SingleCellAnalysis #CancerResearch #Oncology #Biotechnology #Biotech #StemCellResearch #MolecularBiology #GeneTherapy #ResearchAndDevelopment

Happy to share among LinkedIn members about my Editorial roles in some international journals: 1. Editorial Board Member of Scientific reports (Springer Nature) 2. Editorial Borad Members of BMC infectious diseases (Springer) 3. Discover Molecules (Springer) 4. Cell and Development Studies -------and more Role as Review Editors: 1. Frontiers in Immunology 2. Frontiers in Oncology 3. Frontiers in Pharmacology 4. Cancer Immunity and Immunotherapy #Paruluniversity #RDC